TY - JOUR
T1 - School performance and psychiatric comorbidity in juvenile absence epilepsy and juvenile myoclonic epilepsy
T2 - a Danish population-based cohort study
AU - Boesen, Magnus Spangsberg
AU - Børresen, Malene Landbo
AU - Christensen, Søren Kirchhoff
AU - Klein-Petersen, Amalie Wandel
AU - El Mahdaoui, Sahla
AU - Sagar, Malini Vendela
AU - Schou, Emilie
AU - Eltvedt, Anna Korsgaard
AU - Miranda, Maria Jose
AU - Born, Alfred Peter
AU - Uldall, Peter Vilhelm
AU - Thygesen, Lau Caspar
AU - Cacic Hribljan, Melita
N1 - © 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
PY - 2022/9
Y1 - 2022/9
N2 - BACKGROUND: We aimed to determine school performance and psychiatric comorbidity in juvenile absence epilepsy (JAE), juvenile myoclonic epilepsy (JME), and generalized tonic-clonic seizures (GTCS) alone.METHODS: All children (< 18 years) fulfilled International League Against Epilepsy criteria after review of their medical records. Control groups were the pediatric background population or children with non-neurological chronic disease. Outcomes were on school performance and psychiatric comorbidity. We compared mean grade point averages using linear regression and estimated hazard ratios using Cox regression in the remaining analyses. We adjusted for the child's sex, age, and year of birth; and parental highest education, receipt of cash benefits or early retirement.RESULTS: We included 92 JAE, 190 JME, 27 GTCS alone, 15,084 non-neurological chronic disease controls, and population controls. JAE had two times increased hazard for special needs education compared with age-matched population controls (hazard ratio 2.2, 95% CI = 1.1‒4.6, p = 0.03); this was not seen in JME. Compared with population controls, both JAE and JME had lower grade point average in secondary and high school (JME: 9th grade: - 0.5 points, 95% CI = -0.9 to -0.06, p = 0.03; high school: - 0.6 points, 95% CI = -1.3 to -0.1, p = 0.04), and 8% fewer JME and 15% fewer JAE attended high school. Both JME and JAE had higher hazard for redeeming sleep medication compared with non-neurological chronic disease; additionally, JAE had increased hazard for ADHD medicine redemptions.CONCLUSIONS: Both JAE and JME had marginally poorer school performance; performance seemed worse in JAE than in JME. Both JAE and JME had increased use of sleep medication.
AB - BACKGROUND: We aimed to determine school performance and psychiatric comorbidity in juvenile absence epilepsy (JAE), juvenile myoclonic epilepsy (JME), and generalized tonic-clonic seizures (GTCS) alone.METHODS: All children (< 18 years) fulfilled International League Against Epilepsy criteria after review of their medical records. Control groups were the pediatric background population or children with non-neurological chronic disease. Outcomes were on school performance and psychiatric comorbidity. We compared mean grade point averages using linear regression and estimated hazard ratios using Cox regression in the remaining analyses. We adjusted for the child's sex, age, and year of birth; and parental highest education, receipt of cash benefits or early retirement.RESULTS: We included 92 JAE, 190 JME, 27 GTCS alone, 15,084 non-neurological chronic disease controls, and population controls. JAE had two times increased hazard for special needs education compared with age-matched population controls (hazard ratio 2.2, 95% CI = 1.1‒4.6, p = 0.03); this was not seen in JME. Compared with population controls, both JAE and JME had lower grade point average in secondary and high school (JME: 9th grade: - 0.5 points, 95% CI = -0.9 to -0.06, p = 0.03; high school: - 0.6 points, 95% CI = -1.3 to -0.1, p = 0.04), and 8% fewer JME and 15% fewer JAE attended high school. Both JME and JAE had higher hazard for redeeming sleep medication compared with non-neurological chronic disease; additionally, JAE had increased hazard for ADHD medicine redemptions.CONCLUSIONS: Both JAE and JME had marginally poorer school performance; performance seemed worse in JAE than in JME. Both JAE and JME had increased use of sleep medication.
KW - Child
KW - Cohort Studies
KW - Comorbidity
KW - Denmark/epidemiology
KW - Electroencephalography
KW - Epilepsy, Absence/drug therapy
KW - Humans
KW - Myoclonic Epilepsy, Juvenile/epidemiology
KW - Seizures/epidemiology
U2 - 10.1007/s00415-022-11147-2
DO - 10.1007/s00415-022-11147-2
M3 - Article
C2 - 35595971
SN - 0340-5354
VL - 269
SP - 4997
EP - 5007
JO - Journal of Neurology
JF - Journal of Neurology
IS - 9
ER -